# Title

 Food and Drugs. PART 310â€”NEW DRUGS


# ID

 CFR-2018-title21-vol5.Pt. 310


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Money       | [(25000.0, 'USD')]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Constraints | ['greater', 'maximum', 'more than', 'no later than', 'before', 'after', 'prior to', 'minimum', 'less than', 'within', 'exceed']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Duration    | ['10.0 day', '3.0 year', '2.0 year', '10.0 year', '3.0 day', '12.0 year', '1.0 week', '6.0 year', '30.0 day', '15.0 day', '5.0 year', '1.0 year', '4.0 day', '24.0 hour', '5.0 day']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Condition   | ['subject to', 'until', 'as soon as', 'where', 'when', 'unless', 'if']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Entities    | ['Oral', 'Such', 'Important', 'Drugs, HFD-150', 'Disability', 'Research, Office', 'Unique', 'Quinine', 'Treatment', 'Colloidal', 'Food', 'Parenteral', 'Drug', 'Unexpected', 'Cloves', 'Information', 'Vibesate', 'Dicyclomine', 'Approved', 'Anticholinergic', 'Male', 'Research', 'Opportunity', 'Rockville, MD', 'Estrogens', 'Datura', 'Belladonna', 'Benzocaine', 'Atropine', 'Biologics', 'Atropa', 'Certain', 'Androgens', 'Individual', 'Health', 'Allantoin', 'Serious', 'Anise', 'Lobelia', 'Korean', 'Hexadenol', 'G112', 'New', 'Appropriate', 'Rm', 'Lactobacillus', 'Bureau', 'Adverse', 'Tyloxapol']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Date        | ['2018-03-05', '1994-05-16', '1992-12-04', '1999-01-29', '2005-04-18', '1979-12-24', '2018-02-05', '1991-05-07', '2007-04-05', '2003-09-25', '2013-12-17', '2001-10-29', '1962-10-10', '1994-04-21', '2007-10-01', '1990-01-08', '1989-03-06', '2017-09-06', '2004-12-09', '1913-03-04', '2018-01-08', '1976-10-20', '1987-10-02', '1985-12-17', '1998-04-20', '1993-06-18', '1990-08-27', '1976-02-20', '1995-08-23', '2007-04-11', '2012-12-17', '1975-08-25', '1976-11-20', '1994-03-09', '1944-07-01', '2002-11-05', '2004-06-04', '2007-10-11', '1972-03-03', '1995-02-22', '1991-08-05', '1999-09-16', '1998-10-22', '1996-01-29', '1994-03-02', '1990-11-12', '1996-06-19', '1976-08-20', '1995-08-15', '1977-01-20', '1996-10-07', '1975-08-26', '1962-10-09', '1992-12-30', '1990-02-28', '2007-03-29', '1968-01-23', '1993-09-14', '1994-09-23', '1995-10-24', '2010-09-06', '2003-06-06', '1993-12-01', '2018-12-20', '1993-12-09', '1963-01-08', '1999-02-22', '1993-11-10', '1994-06-14', '1992-02-10', '2005-06-06', '2002-12-31', '1993-04-21', '2005-06-09', '1979-04-16', '1994-09-02', '2004-04-19', '1975-07-25'] |


# Structured Analysis With Context

 


## Money

| Money            | Context                                                                                                            |
|:-----------------|:-------------------------------------------------------------------------------------------------------------------|
| (25000.0, 'USD') | (ii) Approved as of April 19, 2004; April 18, 2005, for products with annual sales less than $25,000.              |
| (25000.0, 'USD') | (ii) Approved as of December 9, 2004; June 9, 2005, for products with annual sales less than $25,000.              |
| (25000.0, 'USD') | (C) Approved as of April 11, 2007; October 11, 2007, for products with annual sales less than $25,000.             |
| (25000.0, 'USD') | (B) Ingredients&#8212;Approved as of June 4, 2004; June 6, 2005, for products with annual sales less than $25,000. |
| (25000.0, 'USD') | (B) Ingredients&#8212;Approved as of June 4, 2004; June 6, 2005, for products with annual sales less than $25,000. |
| (25000.0, 'USD') | (B) Ingredients&#8212;Approved as of June 4, 2004; June 6, 2005, for products with annual sales less than $25,000. |
| (25000.0, 'USD') | April 18, 2005, for products with annual sales less than $25,000.                                                  |
| (25000.0, 'USD') | June 6, 2005, for products with annual sales less than $25,000.                                                    |
| (25000.0, 'USD') | June 9, 2005, for products with annual sales less than $25,000.                                                    |
| (25000.0, 'USD') | December 17, 2013, for products with annual sales less than $25,000.                                               |


## Constraints

| Constraints   | Context                                                                                                                         |
|:--------------|:--------------------------------------------------------------------------------------------------------------------------------|
| within        | or harmful amount of the substance contained therein within a reasonable time and not difficult for normal                      |
| within        | or harmful amount of the substance contained therein within a reasonable time and not difficult for normal                      |
| within        | recognized as safe may become a &#8220;new drug&#8221; within the meaning of section 201(p) of said act                         |
| after         | a &#8220;new drug&#8221; if any labeling change made after October 9, 1962, recommends or suggests new conditions               |
| after         | this purpose for a period of 2 years after shipment and will make them available to the                                         |
| within        | (b) of this section is a &#8220;new drug&#8221; within the meaning of section 201(p) of the act                                 |
| more than     | (iv) The preparation contains not  more than 0.325 gram (5 grains) of N-acetyl-p-aminophenol per dosage                         |
| more than     | (iv) The preparation contains not  more than 0.325 gram (5 grains) of N-acetyl-p-aminophenol per dosage                         |
| maximum       | to 12 years of age, one-half of the maximum adult dose or dosage; for children 3 to                                             |
| maximum       | to 12 years of age, one-half of the maximum adult dose or dosage; for children 3 to                                             |
| more than     | age and against use of the drug for more than 10 days, unless such uses are directed by                                         |
| more than     | statement, such as &#8220;Caution: If pain persists for more than 10 days, or redness is present, or in                         |
| more than     | (iv) The preparation contains not  more than 0.5 gram (7.7 grains) of anhydrous sodium gentisate                                |
| maximum       | to 12 years of age, one-half of the maximum  adult dose or dosage.                                                              |
| more than     | (iv) The preparation contains not  more than 0.25 percent of isoamylhydrocupreine and 1.0 percent of                            |
| more than     | preparation is in suppository form, it contains not more than  5.0 milligrams of isoamylhydrocupreine and not                   |
| more than     | preparation is in suppository form, it contains not more than  5.0 milligrams of isoamylhydrocupreine and not                   |
| more than     | The directions provide for the use of not more than two suppositories or two applications of ointment in                        |
| more than     | (iv) The preparation contains not  more than 88 milligrams of phenyltoloxamine dihydrogen citrate (equivalent to                |
| maximum       | to 12 years of age, one-half of the maximum  adult dose or dosage.                                                              |
| exceed        | that continued administration for such use should not exceed  3 days, except as directed by a physician.                        |
| more than     | (iv) The preparation contains not  more than 5 milligrams of dicyclomine hydrochloride per dosage unit,                         |
| more than     | (iv) The preparation contains not  more than 5 milligrams of dicyclomine hydrochloride per dosage unit,                         |
| exceed        | suggested in the directions for use do not exceed 10 milligrams of dicyclomine hydrochloride per dose or                        |
| more than     | (iv) The preparation contains not  more than  5 percent by weight of hexadenol.                                                 |
| more than     | (iv) The preparation contains not  more than 5 grams of sulfur dioxide per 100 milliliters                                      |
| more than     | The directions for use recommend or suggest not more than  two applications a day for not                                       |
| more than     | The directions for use recommend or suggest not more than  two applications a day for not                                       |
| more than     | the recommended route of administration, and delivering not more than  0.1 milliliter of the preparation per drop.              |
| exceed        | tuaminoheptane sulfate content of the preparation does not exceed  10 milligrams per milliliter.                                |
| exceed        | suggested in the directions for use do not exceed the equivalent: For adults, 5 drops of a                                      |
| more than     | recommendations: (a) Clear warning statements against use of more than 5 doses daily, and against use longer than               |
| more than     | (iv) The preparation contains not  more than  13 percent by weight of vibesate.                                                 |
| more than     | (iv) The preparation contains not  more than  1.0 percent of pramoxine hydrochloride.                                           |
| more than     | The directions for use recommend or suggest not more than four applications of the preparation per day, unless                  |
| more than     | (iv) The preparation contains not  more than  50 milligrams of pamabrom per dosage unit.                                        |
| before        | and discomforts that may occur a few days before  and during the menstrual period.                                              |
| exceed        | recommended or suggested in the labeling do not exceed 50 milligrams of pamabrom per dose or 200                                |
| more than     | (iv) The preparation contains not  more than  2.0 percent of diphemanil methylsulfate.                                          |
| more than     | The directions for use recommend or suggest not more than four applications of the preparation per day, unless                  |
| more than     | (iv) The preparation contains not  more than  1.0 percent of dyclonine hydrochloride.                                           |
| more than     | (iv) The preparation contains not  more than  25 milligrams of chlorothen citrate per dosage unit.                              |
| maximum       | to 12 years of age, one-half of the maximum  adult dose or dosage.                                                              |
| exceed        | that continued administration for such use should not exceed  3 days, unless directed by a physician.                           |
| more than     | (iv) The preparation contains not  more than  3.5 milligrams of methoxyphenamine hydrochloride per milliliter.                  |
| maximum       | to 12 years of age, one-half of the maximum  adult dose or dosage.                                                              |
| more than     | (iv) The preparation contains not  more than  1 percent of biphenamine hydrochloride.                                           |
| minimum       | protection and be suitable for self-medication with a minimum  risk of contamination of the solution during use.                |
| after         | for suspending or withdrawing approval of the application. after                                                                |
| prior to      | with representatives of the Food and Drug Administration. prior to                                                              |
| greater       | labeling, but differ from the event because of greater  severity or specificity.                                                |
| greater       | hepatic necrosis would be unexpected (by virtue of greater severity) if the labeling only referred to elevated                  |
| greater       | cerebral vasculitis would be unexpected (by virtue of greater specificity) if the labeling only listed cerebral vascular        |
| no later than | serious and unexpected as soon as possible, but no later than 15 calendar days from initial receipt of the                      |
| within        | 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information                     |
| within        | any appropriate means, each report to the manufacturer within 5 calendar days of its receipt by the                             |
| after         | nonprescription product; (vii) Whether adverse drug experience abated after drug use stopped or dose reduced; (viii) Whether    |
| after         | nonprescription product; (vii) Whether adverse drug experience abated after drug use stopped or dose reduced; (viii) Whether    |
| before        | with this section if provided to the patient before administration of the first oral contraceptive and every                    |
| after         | first oral contraceptive and every 30 days there after , as long as the therapy continues.                                      |
| before        | that the patient should provide to the prescriber before  taking the drug.                                                      |
| before        | unborn child from the use of oral contraceptives before or during early pregnancy; (ii) A statement concerning                  |
| after         | to take the product, information about becoming pregnant after discontinuing use of the drug, a statement that                  |
| after         | of the patient package insert placed prominently immediately after  the last section of the labeling.                           |
| within        | determined by rulemaking procedures to be new drugs within  the meaning of section 201(p) of the act.                           |
| prior to      | or a &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, or for which biologic an          |
| prior to      | or a &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, or for which biologic an          |
| before        | unless an approvable notice was issued on or before August 20, 1976, in which case the exemption                                |
| before        | of the indications listed, shall submit, on or before August 25, 1975 to the Center for Drug                                    |
| before        | Center for Drug Evaluation and Research on or before August 25, 1975 is terminated on August 20,                                |
| before        | Center for Drug Evaluation and Research on or before August 25, 1975 is terminated on August 20,                                |
| before        | Center for Biologics Evaluation and Research on or before August 25, 1975 is terminated on October 20,                          |
| before        | Center for Biologics Evaluation and Research on or before August 25, 1975 is terminated on October 20,                          |
| before        | project, which use had been approved on or before July 25, 1975 in accordance with 10 CFR                                       |
| before        | project, which use had been approved on or before July 25, 1975 in accordance with 10 CFR                                       |
| maximum       | of an Agreement State); (5) The name and maximum amount per subject of the radionuclide used; (6)                               |
| within        | as safe and effective, is a new drug within the meaning of section 201(p) of the act,                                           |
| after         | packaged in a plastic immediate container on or after April 16, 1979, is misbranded unless its labeling                         |
| before        | with this section if provided to the patient before administration of the first estrogen and every 30                           |
| after         | the first estrogen and every 30 days there after , as long as the therapy continues.                                            |
| within        | related indication) is regarded as a new drug within the meaning of section 201(p) of the Federal                               |
| after         | daytime sedative drug product introduced into interstate commerce after December 24, 1979, that is not in compliance            |
| within        | loss prevention is regarded as a new drug within the meaning of section 201(p) of the Federal                                   |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | an aphrodisiac is regarded as a new drug within the meaning of section 201(p) of the Federal                                    |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | insect repellent is regarded as a new drug within the meaning of section 201(p) of the Federal                                  |
| after         | (d) Any such drug product in interstate commerce  after December 17, 1985, that is not in compliance                            |
| within        | this section, is regarded as a new drug within the meaning of section 201(p) of the act,                                        |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | of boils is regarded as a new drug within the meaning of section 201(p) of the Federal                                          |
| after         | with this section is subject to regulatory action. after                                                                        |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | prostatic hypertrophy is regarded as a new drug within the meaning of section 201(p) of the Federal                             |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | an anticholinergic is regarded as a new drug within the meaning of section 201(p) of the Federal                                |
| after         | the subject of an approved new drug application. after                                                                          |
| within        | healing agent is regarded as a new drug within the meaning of section 201(p) of the Federal                                     |
| after         | the subject of an approved new drug application. after                                                                          |
| within        | thumbsucking deterrent is regarded as a new drug within the meaning of section 201(p) of the Federal                            |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | cold sores is regarded as a new drug within the meaning of section 201(p) of the Federal                                        |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | toenail relief is regarded as a new drug within the meaning of section 201(p) of the Federal                                    |
| after         | with this section is subject to regulatory action. after                                                                        |
| after         | with part 358, subpart D of this chapter, after  June 6, 2003.                                                                  |
| within        | stomach acidifier is regarded as a new drug within the meaning of section 201(p) of the Federal                                 |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | of hypophosphatemia is regarded as a new drug within the meaning of section 201(p) of the Federal                               |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | of hyperphosphatemia is regarded as a new drug within the meaning of section 201(p) of the Federal                              |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | pancreatic insufficiency is regarded as a new drug within the meaning of section 201(p) of the Federal                          |
| after         | with this section is subject to regulatory action. after                                                                        |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | smoking deterrent is regarded as a new drug within the meaning of section 201(p) of the Federal                                 |
| after         | with this section is subject to regulatory action. after                                                                        |
| after         | with this section is subject to regulatory action. after                                                                        |
| less than     | April 18, 2005, for products with annual sales less than  $25,000.                                                              |
| less than     | June 9, 2005, for products with annual sales less than  $25,000.                                                                |
| less than     | October 11, 2007, for products with annual sales less than  $25,000.                                                            |
| less than     | June 6, 2005, for products with annual sales less than  $25,000.                                                                |
| less than     | June 6, 2005, for products with annual sales less than  $25,000.                                                                |
| less than     | June 6, 2005, for products with annual sales less than  $25,000.                                                                |
| within        | this section is regarded as a new drug within the meaning of section 210(p) of the Federal                                      |
| after         | or initially delivered for introduction into interstate commerce after the dates specified in paragraphs (d)(1) through (d)(41) |
| after         | to products allowed by &#167;&#8201;358.720(b) of this chapter after  April 5, 2007.                                            |
| less than     | April 18, 2005, for products with annual sales  less than  $25,000.                                                             |
| less than     | June 6, 2005, for products with annual sales  less than  $25,000.                                                               |
| less than     | June 9, 2005, for products with annual sales  less than  $25,000.                                                               |
| less than     | December 17, 2013, for products with annual sales  less than  $25,000.                                                          |
| within        | muscle cramps is regarded as a new drug within the meaning of section 201(p) of the Federal                                     |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | of malaria is regarded as a new drug within the meaning of section 201(p) of the act,                                           |
| after         | with this section is subject to regulatory action. after                                                                        |
| within        | any disease is regarded as a new drug within the meaning of section 201(p) of the Federal                                       |
| after         | with this section is subject to regulatory action. after                                                                        |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5.0 year   | (l) Special packaging as defined in section 2(4) of the Poison Prevention Packaging Act of 1970 means packaging that is designed or constructed to be significantly difficult for children under 5 years of age to open or obtain a toxic or harmful amount of the substance contained therein within a reasonable time and not difficult for normal adults to use properly, but does not mean packaging which all such children cannot open or obtain a toxic or harmful amount within a reasonable time.                                |
| 2.0 year   | (6) The manufacturer or distributor maintains records of all shipments for this purpose for a period of 2 years after shipment and will make them available to the Food and Drug Administration on request.                                                                                                                                                                                                                                                                                                                               |
| 24.0 hour  | (vi) The dosages of N-acetyl-p-aminophenol recommended or suggested in the labeling do not exceed: For adults, 0.65 gram (10 grains) per dose or 2.6 grams (40 grains) per 24-hour period: for children 6 to 12 years of age, one-half of the maximum adult dose or dosage; for children 3 to 6 years of age, one-fifth of the maximum adult dose or dosage.                                                                                                                                                                              |
| 12.0 year  | (vi) The dosages of N-acetyl-p-aminophenol recommended or suggested in the labeling do not exceed: For adults, 0.65 gram (10 grains) per dose or 2.6 grams (40 grains) per 24-hour period: for children 6 to 12 years of age, one-half of the maximum adult dose or dosage; for children 3 to 6 years of age, one-fifth of the maximum adult dose or dosage.                                                                                                                                                                              |
| 6.0 year   | (vi) The dosages of N-acetyl-p-aminophenol recommended or suggested in the labeling do not exceed: For adults, 0.65 gram (10 grains) per dose or 2.6 grams (40 grains) per 24-hour period: for children 6 to 12 years of age, one-half of the maximum adult dose or dosage; for children 3 to 6 years of age, one-fifth of the maximum adult dose or dosage.                                                                                                                                                                              |
| 3.0 year   | (vii) The labeling bears, in juxtaposition with the dosage recommendations, a clear warning statement against administration of the drug to children under 3 years of age and against use of the drug for more than 10 days, unless such uses are directed by a physician.                                                                                                                                                                                                                                                                |
| 10.0 day   | (vii) The labeling bears, in juxtaposition with the dosage recommendations, a clear warning statement against administration of the drug to children under 3 years of age and against use of the drug for more than 10 days, unless such uses are directed by a physician.                                                                                                                                                                                                                                                                |
| 10.0 day   | (viii) If the article is offered for use in arthritis or rheumatism, the labeling prominently bears a statement that the beneficial effects claimed are limited to the temporary relief of minor aches and pains of arthritis and rheumatism and, in juxtaposition with directions for use in such conditions, a conspicuous warning statement, such as &#8220;Caution: If pain persists for more than 10 days, or redness is present, or in conditions affecting children under 12 years of age, consult a physician immediately&#8221;. |
| 12.0 year  | (viii) If the article is offered for use in arthritis or rheumatism, the labeling prominently bears a statement that the beneficial effects claimed are limited to the temporary relief of minor aches and pains of arthritis and rheumatism and, in juxtaposition with directions for use in such conditions, a conspicuous warning statement, such as &#8220;Caution: If pain persists for more than 10 days, or redness is present, or in conditions affecting children under 12 years of age, consult a physician immediately&#8221;. |
| 24.0 hour  | (vi) The dosages of sodium gentisate recommended or suggested in the labeling do not exceed: For adults, 0.5 gram (7.7 grains) per dose of 2.0 grams (31 grains) per 24-hour period; for children 6 to 12 years of age, one-half of the maximum adult dose or dosage.                                                                                                                                                                                                                                                                     |
| 12.0 year  | (vi) The dosages of sodium gentisate recommended or suggested in the labeling do not exceed: For adults, 0.5 gram (7.7 grains) per dose of 2.0 grams (31 grains) per 24-hour period; for children 6 to 12 years of age, one-half of the maximum adult dose or dosage.                                                                                                                                                                                                                                                                     |
| 6.0 year   | (vii) The labeling bears, in juxtaposition with the dosage recommendations, a clear warning statement against administration of the drug to children under 6 years of age and against use of the drug for a prolonged period, except as such uses may be directed by a physician.                                                                                                                                                                                                                                                         |
| 24.0 hour  | (vii) The directions provide for the use of not more than two suppositories or two applications of ointment in a 24-hour period.                                                                                                                                                                                                                                                                                                                                                                                                          |
| 24.0 hour  | (vi) The dosages recommended or suggested in the labeling do not exceed: For adults, 88 milligrams of phenyltoloxamine dihydrogen citrate (equivalent to 50 milligrams of phenyltoloxamine) per dose or 264 milligrams of phenyltoloxamine dihydrogen citrate (equivalent to 150 milligrams of phenyltoloxamine) per 24-hour period; for children 6 to 12 years of age, one-half of the maximum adult dose or dosage.                                                                                                                     |
| 12.0 year  | (vi) The dosages recommended or suggested in the labeling do not exceed: For adults, 88 milligrams of phenyltoloxamine dihydrogen citrate (equivalent to 50 milligrams of phenyltoloxamine) per dose or 264 milligrams of phenyltoloxamine dihydrogen citrate (equivalent to 150 milligrams of phenyltoloxamine) per 24-hour period; for children 6 to 12 years of age, one-half of the maximum adult dose or dosage.                                                                                                                     |
| 6.0 year   | (vii) The labeling bears, in juxtaposition with the dosage recommendations:                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (a) Clear warning statements against administration of the drug to children under 6 years of age, except as directed by a physician, and against driving a car or operating machinery while using the drug, since it may cause drowsiness.                                                                                                                                                                                                                                                                                  |
| 3.0 day    | (b) If the article is offered for temporary relief of the symptoms of colds, a statement that continued administration for such use should not exceed 3 days, except as directed by a physician.                                                                                                                                                                                                                                                                                                                                          |
| 12.0 year  | (v) The preparation is labeled with adequate directions for use only by adults and children over 12 years of age, in the temporary relief of gastric hyperacidity.                                                                                                                                                                                                                                                                                                                                                                        |
| 24.0 hour  | (vi) The dosages recommended or suggested in the directions for use do not exceed 10 milligrams of dicyclomine hydrochloride per dose or 30 milligrams in a 24-hour period.                                                                                                                                                                                                                                                                                                                                                               |
| 12.0 year  | (c) Administration to children under 12 years of age except as directed by a physician.                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1.0 week   | (vi) The directions for use recommend or suggest not more than two applications a day for not more than 1 week, except as directed by a physician.                                                                                                                                                                                                                                                                                                                                                                                        |
| 24.0 hour  | (vii) The dosages recommended or suggested in the directions for use do not exceed the equivalent: For adults, 5 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for children 1 to 6 years of age, 3 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for infants under 1 year of age, 2 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period.                                                                                    |
| 6.0 year   | (vii) The dosages recommended or suggested in the directions for use do not exceed the equivalent: For adults, 5 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for children 1 to 6 years of age, 3 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for infants under 1 year of age, 2 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period.                                                                                    |
| 24.0 hour  | (vii) The dosages recommended or suggested in the directions for use do not exceed the equivalent: For adults, 5 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for children 1 to 6 years of age, 3 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for infants under 1 year of age, 2 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period.                                                                                    |
| 1.0 year   | (vii) The dosages recommended or suggested in the directions for use do not exceed the equivalent: For adults, 5 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for children 1 to 6 years of age, 3 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for infants under 1 year of age, 2 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period.                                                                                    |
| 24.0 hour  | (vii) The dosages recommended or suggested in the directions for use do not exceed the equivalent: For adults, 5 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for children 1 to 6 years of age, 3 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period; for infants under 1 year of age, 2 drops of a 1 percent solution per nostril per dose, and 5 doses in a 24-hour period.                                                                                    |
| 4.0 day    | (viii) The labeling bears, in juxtaposition with the dosage recommendations:                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (a) Clear warning statements against use of more than 5 doses daily, and against use longer than 4 days unless directed by a physician.                                                                                                                                                                                                                                                                                                                                                                                     |
| 24.0 hour  | (vi) The dosages recommended or suggested in the labeling do not exceed 50 milligrams of pamabrom per dose or 200 milligrams per 24-hour period.                                                                                                                                                                                                                                                                                                                                                                                          |
| 24.0 hour  | (vi) The dosages recommended or suggested in the labeling do not exceed: For adults, 25 milligrams of chlorothen citrate per dose or 150 milligrams of chlorothen citrate per 24-hour period; for children 6 to 12 years of age, one-half of the maximum adult dose or dosage.                                                                                                                                                                                                                                                            |
| 12.0 year  | (vi) The dosages recommended or suggested in the labeling do not exceed: For adults, 25 milligrams of chlorothen citrate per dose or 150 milligrams of chlorothen citrate per 24-hour period; for children 6 to 12 years of age, one-half of the maximum adult dose or dosage.                                                                                                                                                                                                                                                            |
| 6.0 year   | (vii) The labeling bears, in juxtaposition with the dosage recommendations:                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (a) Clear warning statements against administration of the drug to children under 6 years of age or exceeding the recommended dosage, unless directed by a physician, and against driving a car or operating machinery while using the drug, since it may cause drowsiness.                                                                                                                                                                                                                                                 |
| 3.0 day    | (b) If the article is offered for the temporary relief of symptoms of colds, a statement that continued administration for such use should not exceed 3 days, unless directed by a physician.                                                                                                                                                                                                                                                                                                                                             |
| 24.0 hour  | (vi) The dosages recommended or suggested in the labeling do not exceed: For adults, 35 milligrams of methoxyphenamine hydrochloride per dose or 140 milligrams of methoxyphenamine hydrochloride per 24-hour period; for children 6 to 12 years of age, one-half of the maximum adult dose or dosage.                                                                                                                                                                                                                                    |
| 12.0 year  | (vi) The dosages recommended or suggested in the labeling do not exceed: For adults, 35 milligrams of methoxyphenamine hydrochloride per dose or 140 milligrams of methoxyphenamine hydrochloride per 24-hour period; for children 6 to 12 years of age, one-half of the maximum adult dose or dosage.                                                                                                                                                                                                                                    |
| 6.0 year   | (vii) The label bears a conspicuous warning to keep the drug out of the reach of children, and the labeling bears, in juxtaposition with the dosage recommendations:                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (a) A clear warning statement against administration of the drug to children under 6 years of age, unless directed by a physician.                                                                                                                                                                                                                                                                                                                                                                                          |
| 15.0 day   | Except as provided in paragraph (e)(2) of this section, 15-day &#8220;Alert reports&#8221; and followup reports, including ICSRs and any ICSR attachments, must be submitted to the Agency in electronic format as described in paragraph (e)(1) of this section.                                                                                                                                                                                                                                                                         |
| 15.0 day   | (1) Postmarketing 15-day &#8220;Alert reports&#8221;.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 15.0 day   | (i) Any person whose name appears on the label of a marketed prescription drug product as its manufacturer, packer, or distributor must report to FDA each adverse drug experience received or otherwise obtained that is both serious and unexpected as soon as possible, but no later than 15 calendar days from initial receipt of the information by the person whose name appears on the label.                                                                                                                                      |
| 15.0 day   | (ii) A person identified in paragraph (c)(1)(i) of this section is not required to submit a 15-day &#8220;Alert report&#8221; for an adverse drug experience obtained from a postmarketing study (whether or not conducted under an investigational new drug application) unless the applicant concludes that there is a reasonable possibility that the drug caused the adverse experience.                                                                                                                                              |
| 15.0 day   | (2) Postmarketing 15-day &#8220;Alert reports&#8221;&#8212;followup.                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 15.0 day   | Each person identified in paragraph (c)(1)(i) of this section must promptly investigate all serious, unexpected adverse drug experiences that are the subject of these postmarketing 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information or as requested by FDA.                                                                                                                                                                                                                  |
| 15.0 day   | Each person identified in paragraph (c)(1)(i) of this section must promptly investigate all serious, unexpected adverse drug experiences that are the subject of these postmarketing 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information or as requested by FDA.                                                                                                                                                                                                                  |
| 5.0 day    | If a packer or distributor elects to submit these adverse drug experience reports to the manufacturer rather than to FDA, it must submit, by any appropriate means, each report to the manufacturer within 5 calendar days of its receipt by the packer or distributor, and the manufacturer must then comply with the requirements of this section even if its name does not appear on the label of the drug product.                                                                                                                    |
| 15.0 day   | (i) Manufacturer, packer, or distributor name and contact office address;                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (ii) Telephone number;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (iii) Report source, such as spontaneous, literature, or study;                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (iv) Date the report was received by manufacturer, packer, or distributor;                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (v) Whether the ICSR is a 15-day &#8220;Alert report&#8221;;                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (vi) Whether the ICSR is an initial report or followup report; and                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (vii) Unique case identification number, which must be the same in the initial report and any subsequent followup report(s).                                                                                                                                                                                                                                                                                                                                                                                                |
| 10.0 year  | (1) Each manufacturer, packer, and distributor must maintain for a period of 10 years records of all adverse drug experiences required under this section to be reported, including raw data and any correspondence relating to the adverse drug experiences, and the records required to be maintained under paragraph (c)(3) of this section.                                                                                                                                                                                           |
| 30.0 day   | (2) Patient package inserts for oral contraceptives dispensed in acute-care hospitals or long-term care facilities will be considered to have been provided in accordance with this section if provided to the patient before administration of the first oral contraceptive and every 30 days thereafter, as long as the therapy continues.                                                                                                                                                                                              |
| 30.0 day   | (3) Patient package inserts for estrogens dispensed in acute-care hospitals or long-term care facilities will be considered to have been provided in accordance with this section if provided to the patient before administration of the first estrogen and every 30 days thereafter, as long as the therapy continues.                                                                                                                                                                                                                  |
| 24.0 hour  | The following claims are examples of some that have been made for orally administered OTC insect repellent drug products: &#8220;Oral mosquito repellent,&#8221; &#8220;mosquitos avoid you,&#8221; &#8220;bugs stay away,&#8221; &#8220;keep mosquitos away for 12 to 24 hours,&#8221; and &#8220;the newest way to fight mosquitos.&#8221; Therefore, any drug product containing ingredients offered for oral use as an insect repellent cannot be generally recognized as safe and effective.                                         |


## Condition

| Condition   | Context                                                                                                                                                           |
|:------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| when        | the act shall be applicable to such terms when  used in the regulations in this part.                                                                             |
| when        | (g) New drug substance means any substance that  when used in the manufacture, processing, or packing of                                                          |
| when        | though such drug is not a new drug when used in another disease or to affect another                                                                              |
| when        | labeling of such drug, even though such drug when used in other dosage, or other method or                                                                        |
| subject to  | Biologics; products  subject to  license control.                                                                                                                 |
| if          | approved application under section 505 of the act. if                                                                                                             |
| subject to  | the new drug applications reviewed and thus are subject to  these notices.                                                                                        |
| subject to  | which are covered by an NDA and thus subject to  each notice.                                                                                                     |
| where       | product, such product is affected by the notice. where                                                                                                            |
| subject to  | drug named in a notice may also be subject to the findings and conclusions in a notice that                                                                       |
| unless      | to a drug in the Drug Efficacy Study unless there has been or is notification in the                                                                              |
| subject to  | Federal Register that a drug will not be subject to an OTC panel review pursuant to &#167;&#167;&#8201;330.10, 330.11,                                            |
| when        | In particular,  when approval of a new drug application is withdrawn                                                                                              |
| if          | (c) Any marketed drug is a &#8220;new drug&#8221;  if any labeling change made after October 9, 1962,                                                             |
| if          | drug&#8221; does not apply to such an article if it has been changed in formulation, manufacture control,                                                         |
| when        | Drug Administration that are qualified and current on when an article is &#8220;not a new drug,&#8221; as                                                         |
| if          | substance, as defined in &#167;&#8201;310.3(g), for such purpose if all of the following conditions are met: (1)                                                  |
| when        | an &#8220;Investigational New Drug Application&#8221; (IND) is required. when                                                                                     |
| subject to  | apply to drugs or their components that are subject to the licensing requirements of the Public Health Service                                                    |
| until       | section 503(b)(1)(B) of the act remains so limited until it is exempted as provided in paragraph (b)                                                              |
| when        | the act shall be exempted from prescription-dispensing requirements when the Commissioner finds such requirements are not necessary                               |
| until       | the meaning of section 201(p) of the act until it has been used to a material extent                                                                              |
| subject to  | public health with respect to the following drugs subject to new drug applications: (1) N-Acetyl-p-aminophenol (acetaminophen, p-hydroxy-acetanilid) preparations |
| if          | (b) of the act is approved for it. if                                                                                                                             |
| if          | (5 grains) of N-acetyl-p-aminophenol per dosage unit, or if it is in liquid form not more than                                                                    |
| unless      | of the drug for more than 10 days, unless  such uses are directed by a physician.                                                                                 |
| if          | 12 years of age, consult a physician immediately&#8221;. if                                                                                                       |
| if          | 12 years of age, consult a physician immediately&#8221;. if                                                                                                       |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| if          | than 20.0 milligrams of zolamine hydrochloride per suppository. if                                                                                                |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| if          | 3 days, except as directed by a physician. if                                                                                                                     |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| if          | milligrams of dicyclomine hydrochloride per dosage unit, or if it is in liquid form not more than                                                                 |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| unless      | daily, and against use longer than 4 days unless  directed by a physician.                                                                                        |
| unless      | or thyroid disease should not use the preparation unless  directed by a physician.                                                                                |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| unless      | burns and on infected, deep, and puncture wounds unless  directed by a physician.                                                                                 |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| unless      | than four applications of the preparation per day, unless  directed by a physician.                                                                               |
| if          | (c) Continued use  if redness, irritation, swelling, or pain persists or increases,                                                                               |
| unless      | redness, irritation, swelling, or pain persists or increases, unless  directed by a physician.                                                                    |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| unless      | than four applications of the preparation per day, unless  directed by a physician.                                                                               |
| if          | persists or increases, discontinue use and consult physician.&#8221; if                                                                                           |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| if          | use, clear warning statements against: (a) Continued use if redness, irritation, swelling, or pain persists or increases,                                         |
| unless      | redness, irritation, swelling, or pain persists or increases, unless  directed by a physician.                                                                    |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| unless      | years of age or exceeding the recommended dosage, unless directed by a physician, and against driving a                                                           |
| if          | exceed 3 days, unless directed by a physician. if                                                                                                                 |
| unless      | for such use should not exceed 3 days, unless  directed by a physician.                                                                                           |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| unless      | drug to children under 6 years of age, unless  directed by a physician.                                                                                           |
| unless      | or thyroid disease should not use the preparation unless  directed by a physician.                                                                                |
| if          | drug in the presence of high fever or if cough persists, since persistent cough as well as                                                                        |
| if          | 505(b) of the act is approved for it. if                                                                                                                          |
| until       | sterile and so packaged as to maintain sterility until  the package is opened.                                                                                    |
| if          | with the dosage recommendations, a clear warning that if irritation occurs, persists, or increases, use of the                                                    |
| unless      | new drug may not be approved for marketing unless it has been shown to be safe and                                                                                |
| subject to  | Any person  subject to the reporting requirements of paragraph (c) of this                                                                                        |
| when        | may be considered a serious adverse drug experience when , based upon appropriate medical judgment, they may                                                      |
| if          | would be unexpected (by virtue of greater severity) if the labeling only referred to elevated hepatic enzymes                                                     |
| if          | would be unexpected (by virtue of greater spec if icity)                                                                                                          |
| as soon as  | otherwise obtained that is both serious and unexpected as soon as possible, but no later than 15 calendar days                                                    |
| unless      | labeling in electronic format as an ICSR attachment unless  it is already on file at FDA.                                                                         |
| unless      | not conducted under an investigational new drug application) unless the applicant concludes that there is a reasonable                                            |
| if          | comply with the requirements of this section even if its name does not appear on the label                                                                        |
| if          | is a health care professional; and (iii) Occupation, if  a health care professional.                                                                              |
| when        | as part of the initial reporter information, even when  the reporter is the patient.                                                                              |
| subject to  | new drug or abbreviated new drug application are subject to  this section.                                                                                        |
| subject to  | The manufacturer of each product  subject to this section must make the notifications required under                                                              |
| subject to  | If the manufacturer of a product  subject to this section fails to provide notification as required                                                               |
| subject to  | list required by &#167;&#8201;314.81(b)(3)(iii)(d) drug products that are subject to this section that it determines to be in                                     |
| if          | have been provided in accordance with this section if provided to the patient before administration of the                                                        |
| if          | contraceptives properly, including information about what to do if the patient forgets to take the product, information                                           |
| subject to  | applications for oral contraceptive drug products that are subject to the requirements of this section are required to                                            |
| when        | Continued distribution under the investigational exemption  when the drugs are intended for established uses will                                                 |
| when        | isotopes should not be distributed under investigational-use labeling when they are actually intended for use in medical                                          |
| unless      | 3, 1972, is terminated on August 20, 1976, unless an approvable notice was issued on or before                                                                    |
| when        | they should not be distributed under investigational-use labeling when they are actually intended for use in medical                                              |
| unless      | 25, 1975 is terminated on August 20, 1976, unless an approvable notice was issued on or before                                                                    |
| unless      | 25, 1975 is terminated on October 20, 1976, unless an approvable notice was issued on or before                                                                   |
| if          | Agreement State) is terminated on February 20, 1976 if the manufacturer of such drug or the sponsor                                                               |
| until       | (1) A statement that additives may be incompatible. until                                                                                                         |
| unless      | on or after April 16, 1979, is misbranded unless its labeling contains a warning that includes the                                                                |
| if          | (2) A statement that,  if additive drugs are introduced into the parenteral system,                                                                               |
| if          | have been provided in accordance with this section if provided to the patient before administration of the                                                        |
| when        | (4) The contraindications to use, i.e.,  when  estrogens should not be used.                                                                                      |
| subject to  | approved applications for estrogen drug products that are subject to the requirements of this section must submit supplements                                     |
| if          | drug product is packaged in unit-dose packaging, and if the immediate container bears labeling but not a                                                          |
| if          | drug product is packaged in unit-dose packaging, and if the immediate container bears labeling but not a                                                          |
| until       | maximizes the likelihood that the warning is intact until all of the dosage units to which it                                                                     |
| where       | the information panel of the retail package label. where                                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| when        | testosterone and methyltestosterone) and estrogens are powerful hormones when administered internally and are not safe for use                                    |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| where       | pituitary, and carried to another organ or tissue, where  it has a specific effect.                                                                               |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| unless      | or initially delivered for introduction into interstate commerce unless it is the subject of an approved new                                                      |
| unless      | or initially delivered for introduction into interstate commerce unless it is the subject of an approved new                                                      |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | * * (42) December 20, 2018, for products subject to  paragraphs (a)(27)(vi) through (x) of this section.                                                          |
| subject to  | is not in compliance with this section is subject to regulatory action if initially introduced or initially delivered                                             |
| if          | with this section is subject to regulatory action if initially introduced or initially delivered for introduction into                                            |
| subject to  | (1) May 7, 1991, for products  subject to paragraphs (a)(1) through (a)(2)(i), (a)(3)(i), (a)(4)(i), (a)(6)(i)(A), (a)(6)(ii)(A),                                 |
| subject to  | (2) February 10, 1992, for products  subject to  paragraph (a)(20) of this section.                                                                               |
| subject to  | (3) December 4, 1992, for products  subject to paragraph (a)(7) of this section that contain menthol                                                              |
| subject to  | (4) February 28, 1990, for products  subject to paragraph (a)(6)(iii) of this section, except those that                                                          |
| subject to  | (5) September 14, 1993, for products  subject to  paragraph (a)(6)(iii) of this section that contain ipecac.                                                      |
| subject to  | (6) December 9, 1993, for products  subject to  paragraph (a)(6)(i)(B) of this section.                                                                           |
| subject to  | (7) March 6, 1989, for products  subject to paragraph (a)(21) of this section, except those that                                                                  |
| subject to  | (8) June 18, 1993, for products  subject to paragraph (a)(21) of this section that contain ophthalmic                                                             |
| subject to  | (9) June 18, 1993, for products  subject to  paragraph (a)(10)(iv) of this section.                                                                               |
| subject to  | (10) June 18, 1993, for products  subject to  paragraph (a)(22)(i) of this section.                                                                               |
| subject to  | (11) November 10, 1993, for products  subject to paragraphs (a)(8)(ii), (a)(10)(v) through (a)(10)(vii), (a)(18)(ii) (except products                             |
| subject to  | (12) March 2, 1994, for products  subject to  paragraph (a)(22)(iii) of this section.                                                                             |
| subject to  | (13) August 5, 1991, for products  subject to paragraph (a)(26) of this section, except for those                                                                 |
| subject to  | (14) September 2, 1994, for products  subject to paragraph (a)(26)(vii) and (a)(26)(x) of this section that                                                       |
| subject to  | (15) September 23, 1994, for products  subject to  paragraph (a)(22)(iv) of this section.                                                                         |
| subject to  | (16) June 14, 1994, for products  subject to  paragraph (a)(25)(ii) of this section.                                                                              |
| subject to  | (17) April 19, 2004, for products  subject to  paragraph (a)(3)(ii) of this section.                                                                              |
| subject to  | (18) August 15, 1995, for products  subject to  paragraph (a)(15)(ii) of this section.                                                                            |
| subject to  | (19) October 2, 1987, for products  subject to  paragraph (a)(6)(iv)(A) of this section.                                                                          |
| subject to  | (20) January 29, 1996, for products  subject to  paragraph (a)(6)(iv)(B) of this section.                                                                         |
| subject to  | (21) April 21, 1994, for products  subject to  paragraph (a)(8)(iii) of this section.                                                                             |
| subject to  | (22) April 21, 1993, for products  subject to paragraph (a)(18)(ii) of this section that contain ferric                                                           |
| subject to  | (23) August 23, 1995, for products  subject to  paragraph (a)(6)(ii)(B) of this section.                                                                          |
| subject to  | (24) October 7, 1996, for products  subject to  paragraph (a)(2)(ii) of this section.                                                                             |
| subject to  | (25) June 19, 1996, for products  subject to  paragraph (a)(6)(iv)(C) of this section.                                                                            |
| subject to  | (26) February 22, 1999, for products  subject to  paragraphs (a)(23)(ii) and (a)(24)(ii) of this section.                                                         |
| subject to  | (27) [Reserved]                                                                                                                                                   |
|             |               (28) October 22, 1998, for products  subject to  paragraphs (a)(27) and (a)(28)(i) of this section.                                                 |
| subject to  | (29) January 29, 1999, for products  subject to  paragraph (a)(12)(iv)(B) of this section.                                                                        |
| subject to  | (30) November 5, 2002, for products  subject to  paragraph (a)(12)(iv)(C) of this section.                                                                        |
| subject to  | (31) December 31, 2002, for products  subject to  paragraph (a)(29)(i) of this section.                                                                           |
| subject to  | (32) June 4, 2004, for products  subject to  paragraphs (a)(18)(i)(B), (a)(18)(v)(B), and (a)(18)(vi)(B) of this section.                                         |
| subject to  | (33) October 29, 2001, for products  subject to  paragraph (a)(6)(iv)(D) of this section.                                                                         |
| subject to  | (34) December 9, 2004, for products  subject to  paragraph (a)(4)(ii) of this section.                                                                            |
| subject to  | (35) [Reserved]                                                                                                                                                   |
|             |               (36) November 5, 2002, for products  subject to  paragraph (a)(28)(ii) of this section.                                                             |
| subject to  | (37) September 25, 2003, for products  subject to  paragraph (a)(26)(xi) of this section.                                                                         |
| subject to  | (38) October 1, 2007, for products  subject to  paragraph (a)(12)(i)(B) of this section.                                                                          |
| subject to  | (39) September 6, 2010, for products  subject to paragraph (a)(18)(ii) of this section that contain calcium                                                       |
| subject to  | (40) December 17, 2012, for products  subject to  paragraph (a)(29)(ii) of this section.                                                                          |
| subject to  | (41) September 6, 2017, for products  subject to  paragraph (a)(27)(iii) or (iv) of this section.                                                                 |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |
| subject to  | is not in compliance with this section is subject to  regulatory action.                                                                                          |


## Entities

| Entities         | Context                                                                                                                                      |
|:-----------------|:---------------------------------------------------------------------------------------------------------------------------------------------|
| Food             | Food  and Drugs.                                                                                                                             |
| Health           | (b) Department means the Department of  Health  and Human Services.                                                                          |
| Health           | (c) Secretary means the Secretary of  Health  and Human Services.                                                                            |
| Food             | (d) Commissioner means the Commissioner of  Food  and Drugs.                                                                                 |
| New              | (g)  New drug substance means any substance that when used                                                                                   |
| Biologics        | Biologics ; products subject to license control.                                                                                             |
| Opportunity      | Study Implementation (DESI) Notices and as Notices of Opportunity  for Hearing.                                                              |
| Research, Office | and Drug Administration, Center for Drug Evaluation and Research, Office of Compliance, 10903 New Hampshire Ave., Silver Spring,             |
| Appropriate      | Appropriate action, including referral to purchasing officials of various                                                                    |
| New              | New  drug status opinions; statement of policy.                                                                                              |
| New              | New  drug substances intended for hypersensitivity testing.                                                                                  |
| New              | (c)  New drug status of drugs exempted from the prescription                                                                                 |
| Dicyclomine      | (5)-(7) [Reserved]                                                                                                                           |
|                  |               (8)  Dicyclomine  hydrochloride (1-cyclohexylhexahydrobenzoic acid.                                                            |
| Hexadenol        | (9)-(10) [Reserved]                                                                                                                          |
|                  |               (11)  Hexadenol (a mixture of tetracosanes and their oxidation products)                                                       |
| Vibesate         | (17) [Reserved]                                                                                                                              |
|                  |               (18)  Vibesate (a mixture of copolymers of hydroxy-vinyl chlorideacetate, sebacic                                              |
| Tyloxapol        | (28)  Tyloxapol (an alkylarylpolyether alcohol) and benzalkonium chloride ophthalmic preparations                                            |
| Adverse          | Adverse  drug experience.                                                                                                                    |
| Disability       | Disability .                                                                                                                                 |
| Individual       | Individual  case safety report (ICSR).                                                                                                       |
| Serious          | Serious  adverse drug experience.                                                                                                            |
| Important        | Important medical events that may not result in death,                                                                                       |
| Unexpected       | Unexpected  adverse drug experience.                                                                                                         |
| Unexpected       | &#8220; Unexpected ,&#8221; as used in this definition, refers to                                                                            |
| Unique           | an initial report or followup report; and (vii) Unique case identification number, which must be the same                                    |
| Research         | directed to the Center for Drug Evaluation and Research , Division of Reproductive and Urologic Products, Food                               |
| Such             | Such labeling may be put into use without advance                                                                                            |
| Certain          | Certain  drugs accorded new drug status through rulemaking procedures.                                                                       |
| Food             | 8, 1963 (28 FR 183), the Commissioner of Food and Drugs exempted investigational radioactive new drugs from                                  |
| Such             | Such use may include, among others, the uses in                                                                                              |
| Research         | 1975 to the Center for Drug Evaluation and Research , Food and Drug Administration, 5600 Fishers Lane,                                       |
| Rockville, MD    | Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, a new drug application or a &#8220;Investigational           |
| Research         | and Drug Administration, Center for Biologics Evaluation and Research , Document Control Center, 10903 New Hampshire Ave.,                   |
| Rm               | 71,  Rm .                                                                                                                                    |
| G112             | G112 , Silver Spring, MD 20993-0002, in lieu of                                                                                              |
| Bureau           | 25, 1975 to the Food and Drug Administration, Bureau of Drugs, HFD-150, 5600 Fishers Lane, Rockville, MD                                     |
| Drugs, HFD-150   | to the Food and Drug Administration, Bureau of Drugs, HFD-150 , 5600 Fishers Lane, Rockville, MD 20857, the                                  |
| Rockville, MD    | Administration, Bureau of Drugs, HFD-150, 5600 Fishers Lane, Rockville, MD 20857, the following information: (1) The research project        |
| Parenteral       | Parenteral  drug products in plastic containers.                                                                                             |
| Research         | directed to the Center for Drug Evaluation and Research , Division of Reproductive and Urologic Products, Food                               |
| Such             | Such labeling may be put into use without advance                                                                                            |
| Drug             | Drug  products containing iron or iron salts.                                                                                                |
| Drug             | Drug products containing elemental iron or iron salts as                                                                                     |
| Drug             | Drug  products marketed as over-the-counter (OTC) daytime sedatives.                                                                         |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Anise            | Anise , cantharides, don qual, estrogens, fennel, ginseng, golden                                                                            |
| Korean           | qual, estrogens, fennel, ginseng, golden seal, gotu kola, Korean ginseng, licorice, mandrake, methyltestosterone, minerals, nux vomica, Pega |
| Androgens        | Androgens (e.g., testosterone and methyltestosterone) and estrogens are powerful                                                             |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Estrogens        | Estrogens , progesterone, pregnenolone, and pregnenolone acetate have been                                                                   |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Treatment        | Treatment is defined as reducing the size of a                                                                                               |
| Treatment        | Treatment has involved the use of &#8220;drawing salves&#8221; for                                                                           |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) to                                                                |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Atropa           | belladonna alkaloids, and belladonna alkaloids as contained in Atropa belladonna and Datura stramonium have been present as                  |
| Datura           | belladonna alkaloids as contained in Atropa belladonna and Datura stramonium have been present as ingredients in cough-cold                  |
| Anticholinergic  | Anticholinergic drugs have been marketed OTC in cough-cold drug                                                                              |
| Atropine         | Atropine sulfate for oral use as an anticholinergic is                                                                                       |
| Belladonna       | Belladonna alkaloids for inhalation use, as contained in Atropa                                                                              |
| Atropa           | Belladonna alkaloids for inhalation use, as contained in  Atropa belladonna and Datura stramonium, are neither safe nor                      |
| Datura           | inhalation use, as contained in Atropa belladonna and Datura stramonium, are neither safe nor effective as an                                |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Oral             | Oral wound healing agents have been marketed as aids                                                                                         |
| Allantoin        | Allantoin , carbamide peroxide in anhydrous glycerin, water soluble                                                                          |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Lactobacillus    | (a) l-lysine (lysine, lysine hydrochloride),  Lactobacillus  acidophilus, and                                                                |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Benzocaine       | Benzocaine , chlorobutanol, chloroxylenol, dibucaine, tannic acid, and urea                                                                  |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Information      | Information on this process is not included in an                                                                                            |
| Information      | Information on the product's formulation, manufacture, quality control procedures,                                                           |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Cloves           | Cloves , coriander, eucalyptus oil, ginger (Jamaica), lemon oil                                                                              |
| Lobelia          | of lobeline sulfate or natural lobelia alkaloids or Lobelia inflata herb), menthol, methyl salicylate, povidone-silver nitrate, quinine      |
| Lobelia          | of lobeline sulfate or natural lobelia alkaloids or Lobelia inflata herb), povidone-silver nitrate, silver acetate, or any                   |
| Drug             | Drug products containing certain active ingredients offered over-the-counter (OTC)                                                           |
| Approved         | Approved  as of December 20, 2018.                                                                                                           |
| Approved         | Approved  as of December 20, 2018.                                                                                                           |
| Approved         | Approved  as of December 20, 2018.                                                                                                           |
| Drug             | Drug products containing certain active ingredients offered over-the-counter (OTC)                                                           |
| Male             | (iii)  Male  genital desensitizer drug products.                                                                                             |
| Approved         | Approved  as of September 6, 2017.                                                                                                           |
| Approved         | Approved  as of September 6, 2017.                                                                                                           |
| Drug             | Drug products containing active ingredients offered over-the-counter (OTC) for                                                               |
| Quinine          | Quinine sulfate may cause unpredictable serious and life-threatening hypersensitivity                                                        |
| Drug             | Drug products containing quinine offered over-the-counter (OTC) for the                                                                      |
| Quinine          | Quinine is no longer the drug of choice for                                                                                                  |
| Drug             | Drug products containing colloidal silver ingredients or silver salts                                                                        |
| Colloidal        | (a)  Colloidal silver ingredients and silver salts have been marketed                                                                        |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1913-03-04 | (a) If a drug has an approved license under section 351 of the Public Health Service Act (42 U.S.C. 262 et seq.) or under the animal virus, serum, and toxin law of March 4, 1913 (21 U.S.C. 151 et seq.), it is not required to have an approved application under section 505 of the act.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1962-10-10 | In particular, when approval of a new drug application is withdrawn under provisions of section 505(e) of the Federal Food, Drug, and Cosmetic Act, a drug generally recognized as safe may become a &#8220;new drug&#8221; within the meaning of section 201(p) of said act as amended by the Kefauver-Harris Act on October 10, 1962.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1968-01-23 | This is of special importance by reason of proposed actions to withdraw approval of new drug applications for lack of substantial evidence of effectiveness as a result of reports of the National Academy of Sciences&#8212;National Research Council on its review of drug effectiveness; for example, see the notice published in the Federal Register of January 23, 1968 (33 FR 818), regarding rutin, quercetin, et al.                                                                                                                                                                                                                                                                                                                                                                                                         |
| 1962-10-09 | (c) Any marketed drug is a &#8220;new drug&#8221; if any labeling change made after October 9, 1962, recommends or suggests new conditions of use under which the drug is not generally recognized as safe and effective by qualified experts.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2018-02-05 | (2) Sodium gentisate (sodium-2, 5-dihydroxybenzoate) preparations meeting all the following conditions:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (i) The sodium gentisate is prepared, with or without other drugs, in tablet or other dosage form suitable for oral use in self-medication, and containing no drug limited to prescription sale under the provisions of section 503(b)(1) of the act.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 2018-01-08 | (20) [Reserved]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (21) Pamabrom (2-amino-2-methylpropanol-1-8-bromotheophyllinate) preparations meeting all the following conditions:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (i) The pamabrom is prepared with appropriate amounts of a suitable analgesic and with or without other drugs, in tablet or other dosage form suitable for oral use in self-medication, and containing no drug limited to prescription sale under the provisions of section 503(b)(1) of the act.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 2018-03-05 | (5) Certain halogenated salicylanilides (tribromsalan (TBS, 3,4&#8242;,5-tribromosalicylanilide), dibromsalan (DBS, 4&#8242;, 5-dibromosalicylanilide), metabromsalan (MBS, 3, 5-dibromosalicylanilide), and 3,3&#8242;, 4,5&#8242;-tetrachlorosalicylanilide (TC-SA)) as an ingredient in drug products.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1963-01-08 | (a) On January 8, 1963 (28 FR 183), the Commissioner of Food and Drugs exempted investigational radioactive new drugs from part 312 of this chapter provided they were shipped in complete conformity with the regulations issued by the Nuclear Regulatory Commission.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1972-03-03 | (2) The exemption referred to in paragraph (a) of this section, as applied to any drug or biologic containing any of the isotopes listed in paragraph (c) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, is terminated on March 3, 1972, except as provided in paragraph (d)(3) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1972-03-03 | (3) The exemption referred to in paragraph (a) of this section, as applied to any drug or biologic containing any of the isotopes listed in paragraph (c) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, for which drug a new drug application or a &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, or for which biologic an application for product license or &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, is terminated on August 20, 1976, unless an approvable notice was issued on or before August 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on November 20, 1976, whichever occurs first. |
| 1972-03-03 | (3) The exemption referred to in paragraph (a) of this section, as applied to any drug or biologic containing any of the isotopes listed in paragraph (c) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, for which drug a new drug application or a &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, or for which biologic an application for product license or &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, is terminated on August 20, 1976, unless an approvable notice was issued on or before August 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on November 20, 1976, whichever occurs first. |
| 1976-08-20 | (3) The exemption referred to in paragraph (a) of this section, as applied to any drug or biologic containing any of the isotopes listed in paragraph (c) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, for which drug a new drug application or a &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, or for which biologic an application for product license or &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, is terminated on August 20, 1976, unless an approvable notice was issued on or before August 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on November 20, 1976, whichever occurs first. |
| 1976-08-20 | (3) The exemption referred to in paragraph (a) of this section, as applied to any drug or biologic containing any of the isotopes listed in paragraph (c) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, for which drug a new drug application or a &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, or for which biologic an application for product license or &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, is terminated on August 20, 1976, unless an approvable notice was issued on or before August 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on November 20, 1976, whichever occurs first. |
| 1976-11-20 | (3) The exemption referred to in paragraph (a) of this section, as applied to any drug or biologic containing any of the isotopes listed in paragraph (c) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, for which drug a new drug application or a &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, or for which biologic an application for product license or &#8220;Investigational New Drug Application&#8221; was submitted prior to March 3, 1972, is terminated on August 20, 1976, unless an approvable notice was issued on or before August 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on November 20, 1976, whichever occurs first. |
| 1975-08-25 | (3) Any manufacturer or distributor interested in continuing to ship in interstate commerce drugs containing the isotopes listed in paragraph (f)(1) of this section for any of the indications listed, shall submit, on or before August 25, 1975 to the Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, a new drug application or a &#8220;Investigational New Drug Application&#8221; for each such drug for which the manufacturer or distributor does not have an approved new drug application pursuant to section 505(b) of the act.                                                                                                                                                                                                                            |
| 1975-08-26 | (4) The exemption referred to in paragraph (a) of this section, as applied to any drug or biologic containing any of the isotopes listed in paragraph (f)(1) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, is terminated on August 26, 1975 except as provided in paragraph (f)(5) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1975-08-25 | (5)(i) Except as provided in paragraph (f)(5)(ii) of this section, the exemption referred to in paragraph (a) of this section, as applied to any drug containing any of the isotopes listed in paragraph (f)(1) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, for which drug a new drug application or &#8220;Investigational New Drug Application&#8221; was submitted to the Center for Drug Evaluation and Research on or before August 25, 1975 is terminated on August 20, 1976, unless an approvable notice was issued on or before August 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on November 20, 1976, whichever occurs first.                                              |
| 1976-08-20 | (5)(i) Except as provided in paragraph (f)(5)(ii) of this section, the exemption referred to in paragraph (a) of this section, as applied to any drug containing any of the isotopes listed in paragraph (f)(1) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, for which drug a new drug application or &#8220;Investigational New Drug Application&#8221; was submitted to the Center for Drug Evaluation and Research on or before August 25, 1975 is terminated on August 20, 1976, unless an approvable notice was issued on or before August 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on November 20, 1976, whichever occurs first.                                              |
| 1976-08-20 | (5)(i) Except as provided in paragraph (f)(5)(ii) of this section, the exemption referred to in paragraph (a) of this section, as applied to any drug containing any of the isotopes listed in paragraph (f)(1) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, for which drug a new drug application or &#8220;Investigational New Drug Application&#8221; was submitted to the Center for Drug Evaluation and Research on or before August 25, 1975 is terminated on August 20, 1976, unless an approvable notice was issued on or before August 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on November 20, 1976, whichever occurs first.                                              |
| 1976-11-20 | (5)(i) Except as provided in paragraph (f)(5)(ii) of this section, the exemption referred to in paragraph (a) of this section, as applied to any drug containing any of the isotopes listed in paragraph (f)(1) of this section, in the &#8220;chemical form&#8221; and intended for the uses stated, for which drug a new drug application or &#8220;Investigational New Drug Application&#8221; was submitted to the Center for Drug Evaluation and Research on or before August 25, 1975 is terminated on August 20, 1976, unless an approvable notice was issued on or before August 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on November 20, 1976, whichever occurs first.                                              |
| 1975-08-25 | (ii) The exemption referred to in paragraph (a) of this section, as applied to any biologic containing any of the isotopes listed in paragraph (f)(1) of this section in the &#8220;chemical form&#8221; and intended for the uses stated, for which biologic an application for product license or &#8220;Investigational New Drug Application&#8221; was submitted to the Center for Biologics Evaluation and Research on or before August 25, 1975 is terminated on October 20, 1976, unless an approvable notice was issued on or before October 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on January 20, 1977, whichever occurs first.                                                                                   |
| 1976-10-20 | (ii) The exemption referred to in paragraph (a) of this section, as applied to any biologic containing any of the isotopes listed in paragraph (f)(1) of this section in the &#8220;chemical form&#8221; and intended for the uses stated, for which biologic an application for product license or &#8220;Investigational New Drug Application&#8221; was submitted to the Center for Biologics Evaluation and Research on or before August 25, 1975 is terminated on October 20, 1976, unless an approvable notice was issued on or before October 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on January 20, 1977, whichever occurs first.                                                                                   |
| 1976-10-20 | (ii) The exemption referred to in paragraph (a) of this section, as applied to any biologic containing any of the isotopes listed in paragraph (f)(1) of this section in the &#8220;chemical form&#8221; and intended for the uses stated, for which biologic an application for product license or &#8220;Investigational New Drug Application&#8221; was submitted to the Center for Biologics Evaluation and Research on or before August 25, 1975 is terminated on October 20, 1976, unless an approvable notice was issued on or before October 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on January 20, 1977, whichever occurs first.                                                                                   |
| 1977-01-20 | (ii) The exemption referred to in paragraph (a) of this section, as applied to any biologic containing any of the isotopes listed in paragraph (f)(1) of this section in the &#8220;chemical form&#8221; and intended for the uses stated, for which biologic an application for product license or &#8220;Investigational New Drug Application&#8221; was submitted to the Center for Biologics Evaluation and Research on or before August 25, 1975 is terminated on October 20, 1976, unless an approvable notice was issued on or before October 20, 1976, in which case the exemption is terminated either upon the subsequent issuance of a nonapprovable notice for the new drug application or on January 20, 1977, whichever occurs first.                                                                                   |
| 1975-07-25 | (g) The exemption referred to in paragraph (a) of this section, as applied to any drug intended solely for investigational use as part of a research project, which use had been approved on or before July 25, 1975 in accordance with 10 CFR 35.11 (or equivalent regulation of an Agreement State) is terminated on February 20, 1976 if the manufacturer of such drug or the sponsor of the investigation of such drug submits on or before August 25, 1975 to the Food and Drug Administration, Bureau of Drugs, HFD-150, 5600 Fishers Lane, Rockville, MD 20857, the following information:                                                                                                                                                                                                                                     |
|            |               (1) The research project title;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (2) A brief description of the purpose of the project;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (3) The name of the investigator responsible;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (4) The name and license number of the institution holding the specific license under 10 CFR 35.11 (or equivalent regulation of an Agreement State);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (5) The name and maximum amount per subject of the radionuclide used;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (6) The number of subjects involved; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (7) The date on which the administration of the radioactive drugs is expected to be completed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1976-02-20 | (g) The exemption referred to in paragraph (a) of this section, as applied to any drug intended solely for investigational use as part of a research project, which use had been approved on or before July 25, 1975 in accordance with 10 CFR 35.11 (or equivalent regulation of an Agreement State) is terminated on February 20, 1976 if the manufacturer of such drug or the sponsor of the investigation of such drug submits on or before August 25, 1975 to the Food and Drug Administration, Bureau of Drugs, HFD-150, 5600 Fishers Lane, Rockville, MD 20857, the following information:                                                                                                                                                                                                                                     |
|            |               (1) The research project title;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (2) A brief description of the purpose of the project;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (3) The name of the investigator responsible;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (4) The name and license number of the institution holding the specific license under 10 CFR 35.11 (or equivalent regulation of an Agreement State);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (5) The name and maximum amount per subject of the radionuclide used;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (6) The number of subjects involved; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (7) The date on which the administration of the radioactive drugs is expected to be completed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1975-08-25 | (g) The exemption referred to in paragraph (a) of this section, as applied to any drug intended solely for investigational use as part of a research project, which use had been approved on or before July 25, 1975 in accordance with 10 CFR 35.11 (or equivalent regulation of an Agreement State) is terminated on February 20, 1976 if the manufacturer of such drug or the sponsor of the investigation of such drug submits on or before August 25, 1975 to the Food and Drug Administration, Bureau of Drugs, HFD-150, 5600 Fishers Lane, Rockville, MD 20857, the following information:                                                                                                                                                                                                                                     |
|            |               (1) The research project title;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (2) A brief description of the purpose of the project;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (3) The name of the investigator responsible;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (4) The name and license number of the institution holding the specific license under 10 CFR 35.11 (or equivalent regulation of an Agreement State);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (5) The name and maximum amount per subject of the radionuclide used;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (6) The number of subjects involved; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (7) The date on which the administration of the radioactive drugs is expected to be completed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1975-08-26 | (h) The exemption referred to in paragraph (a) of this section, as applied to any drug not referred to in paragraphs (d), (f), and (g) of this section, is terminated on August 26, 1975.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1979-04-16 | (c) Until the results of compatibility studies are evaluated, a large volume parenteral drug product for intravenous use in humans that is packaged in a plastic immediate container on or after April 16, 1979, is misbranded unless its labeling contains a warning that includes the following information:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (1) A statement that additives may be incompatible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1944-07-01 | (d) This section does not apply to a biological product licensed under the Public Health Service Act of July 1, 1944 (42 U.S.C. 201).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 1979-12-24 | (d) Any OTC daytime sedative drug product introduced into interstate commerce after December 24, 1979, that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1990-01-08 | (d) After January 8, 1990, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1990-01-08 | (d) After January 8, 1990, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1985-12-17 | (d) Any such drug product in interstate commerce after December 17, 1985, that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1994-03-09 | (d) After March 9, 1994, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 1991-05-07 | (d) After May 7, 1991, any such OTC drug product that contains aminacrine hydrochloride, bismuth subnitrate, calomel, camphor, cholesterol, ergot fluid extract, hexachlorophene, isobutamben, juniper tar (oil of cade), lanolin, magnesium sulfate, menthol, methyl salicylate, oxyguinoline sulfate, petrolatum, phenol, pine tar, rosin, rosin cerate, sassafras oil, thymol, or zinc oxide initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                    |
| 1994-05-16 | (e) After May 16, 1994, any such OTC drug product that contains benzocaine, ichthammol, sulfur, or triclosan initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1990-08-27 | (d) After August 27, 1990, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1994-03-02 | (d) After March 2, 1994, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 1992-12-30 | (d) After December 30, 1992, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1994-03-09 | (d) After March 9, 1994, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2003-06-06 | (e) This section does not apply to sodium sulfide labeled, represented, or promoted for OTC topical use for ingrown toenail relief in accordance with part 358, subpart D of this chapter, after June 6, 2003.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 1990-11-12 | (d) After November 12, 1990, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1990-11-12 | (d) After November 12, 1990, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1991-05-07 | (d) After May 7, 1991, any such OTC drug product that contains hemicellulase initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1995-10-24 | (e) After October 24, 1995, any such OTC drug product that contains pancreatin or pancrelipase initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1991-05-07 | (d) After May 7, 1991, any such OTC drug product containing cloves, coriander, eucalyptus oil, ginger (Jamaica), lemon oil (terpeneless), licorice root extract, menthol, methyl salicylate, quinine ascorbate, silver nitrate, and/or thymol initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1993-12-01 | After December 1, 1993, any such OTC drug product containing lobeline (in the form of lobeline sulfate or natural lobelia alkaloids or Lobelia inflata herb), povidone-silver nitrate, silver acetate, or any other ingredients initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2018-12-20 | Approved as of December 20, 2018.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2018-12-20 | Approved as of December 20, 2018.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2018-12-20 | Approved as of December 20, 2018.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2018-12-20 | (d) * * *                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |                     (42) December 20, 2018, for products subject to paragraphs (a)(27)(vi) through (x) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1991-05-07 | (2) Anticaries drug products&#8212;(i) Approved as of May 7, 1991.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1996-10-07 | (ii) Approved as of October 7, 1996.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1991-05-07 | (3) Antidiarrheal drug products&#8212;(i) Approved as of May 7, 1991.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2004-04-19 | (ii) Approved as of April 19, 2004; April 18, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2005-04-18 | (ii) Approved as of April 19, 2004; April 18, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 1991-05-07 | (4) Antiperspirant drug products&#8212;(i) Ingredients&#8212;Approved as of May 7, 1991.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2004-12-09 | (ii) Approved as of December 9, 2004; June 9, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2005-06-09 | (ii) Approved as of December 9, 2004; June 9, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 1991-05-07 | (ii) Nasal decongestant drug products&#8212;(A) Approved as of May 7, 1991.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1995-08-23 | (B) Approved as of August 23, 1995.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 2007-04-11 | (C) Approved as of April 11, 2007; October 11, 2007, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 2007-10-11 | (C) Approved as of April 11, 2007; October 11, 2007, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1987-10-02 | (iv) Bronchodilator drug products&#8212;(A) Approved as of October 2, 1987.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1996-01-29 | (B) Approved as of January 29, 1996.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1996-06-19 | (C) Approved as of June 19, 1996.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2001-10-29 | (D) Approved as of October 29, 2001.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1991-05-07 | (8) Digestive aid drug products&#8212;(i) Approved as of May 7, 1991.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 1993-11-10 | (ii) Approved as of November 10, 1993.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 2007-03-29 | (i)(B) Bulk laxatives&#8212;Approved as of March 29, 2007.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 1991-05-07 | (iv)(A) Stimulant laxatives&#8212;Approved as of May 7, 1991.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 1999-01-29 | (iv)(B) Stimulant laxatives&#8212;Approved as of January 29, 1999.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2002-11-05 | (C) Stimulant laxatives&#8212;Approved as of November 5, 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 1991-05-07 | (15) Topical otic drug products&#8212;(i) For the prevention of swimmer's ear and for the drying of water-clogged ears, approved as of May 7, 1991.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1995-08-15 | (ii) For the prevention of swimmer's ear, approved as of August 15, 1995.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1991-05-07 | (18) Skin protectant drug products&#8212;(i)(A) Ingredients&#8212;Approved as of May 7, 1991.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 2004-06-04 | (B) Ingredients&#8212;Approved as of June 4, 2004; June 6, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2005-06-06 | (B) Ingredients&#8212;Approved as of June 4, 2004; June 6, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1993-11-10 | (v) Insect bite and sting drug products&#8212;(A) Ingredients&#8212;Approved as of November 10, 1993.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2004-06-04 | (B) Ingredients&#8212;Approved as of June 4, 2004; June 6, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2005-06-06 | (B) Ingredients&#8212;Approved as of June 4, 2004; June 6, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1993-11-10 | (vi) Poison ivy, poison oak, and poison sumac drug products&#8212;(A) Ingredients&#8212;Approved as of November 10, 1993.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2004-06-04 | (B) Ingredients&#8212;Approved as of June 4, 2004; June 6, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2005-06-06 | (B) Ingredients&#8212;Approved as of June 4, 2004; June 6, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1993-11-10 | (23) Internal analgesic drug products&#8212;(i) Approved as of November 10, 1993.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1999-02-22 | (ii) Approved as of February 22, 1999.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1993-11-10 | (24) Orally administered menstrual drug products&#8212;(i) Approved as of November 10, 1993.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1999-02-22 | (ii) Approved as of February 22, 1999.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1993-11-10 | (25) Pediculicide drug products&#8212;(i) Approved as of November 10, 1993.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1994-06-14 | (ii) Approved as of June 14, 1994.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2017-09-06 | Approved as of September 6, 2017.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2017-09-06 | Approved as of September 6, 2017.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1998-10-22 | (28) Vaginal contraceptive drug products&#8212;(i) Approved as of October 22, 1998.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 2002-11-05 | (ii) Approved as of November 5, 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 1991-05-07 | (1) May 7, 1991, for products subject to paragraphs (a)(1) through (a)(2)(i), (a)(3)(i), (a)(4)(i), (a)(6)(i)(A), (a)(6)(ii)(A), (a)(7) (except as covered by paragraph (d)(3) of this section), (a)(8)(i), (a)(10)(i) through (a)(10)(iii), (a)(12)(i)(A), (a)(12)(ii) through (a)(12)(iv)(A), (a)(14) through (a)(15)(i), (a)(16) through (a)(18)(i)(A), (a)(18)(ii) (except as covered by paragraph (d)(22) of this section), (a)(18)(iii), (a)(18)(iv), (a)(18)(v)(A), and (a)(18)(vi)(A) of this section.                                                                                                                                                                                                                                                                                                                        |
| 1992-02-10 | (2) February 10, 1992, for products subject to paragraph (a)(20) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1992-12-04 | (3) December 4, 1992, for products subject to paragraph (a)(7) of this section that contain menthol as an antipruritic in combination with the antidandruff ingredient coal tar identified in &#167;&#8201;358.710(a)(1) of this chapter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2007-04-05 | This section does not apply to products allowed by &#167;&#8201;358.720(b) of this chapter after April 5, 2007.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1990-02-28 | (4) February 28, 1990, for products subject to paragraph (a)(6)(iii) of this section, except those that contain ipecac.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1993-09-14 | (5) September 14, 1993, for products subject to paragraph (a)(6)(iii) of this section that contain ipecac.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 1993-12-09 | (6) December 9, 1993, for products subject to paragraph (a)(6)(i)(B) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 1989-03-06 | (7) March 6, 1989, for products subject to paragraph (a)(21) of this section, except those that contain ophthalmic anti-infective ingredients listed in paragraph (a)(21)(ii).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 1993-06-18 | (8) June 18, 1993, for products subject to paragraph (a)(21) of this section that contain ophthalmic anti-infective ingredients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1993-06-18 | (9) June 18, 1993, for products subject to paragraph (a)(10)(iv) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1993-06-18 | (10) June 18, 1993, for products subject to paragraph (a)(22)(i) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1993-11-10 | (11) November 10, 1993, for products subject to paragraphs (a)(8)(ii), (a)(10)(v) through (a)(10)(vii), (a)(18)(ii) (except products that contain ferric subsulfate as covered by paragraph (d)(22) of this section and except products that contain calcium acetate monohydrate as covered by paragraph (d)(39) of this section) through (a)(18)(v)(A), (a)(18)(vi)(A), (a)(22)(ii), (a)(23)(i), (a)(24)(i), and (a)(25) of this section.                                                                                                                                                                                                                                                                                                                                                                                            |
| 1994-03-02 | (12) March 2, 1994, for products subject to paragraph (a)(22)(iii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1991-08-05 | (13) August 5, 1991, for products subject to paragraph (a)(26) of this section, except for those that contain live yeast cell derivative and a combination of hydrocortisone and pramoxine hydrochloride.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1994-09-02 | (14) September 2, 1994, for products subject to paragraph (a)(26)(vii) and (a)(26)(x) of this section that contain live yeast cell derivative.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 1994-09-23 | (15) September 23, 1994, for products subject to paragraph (a)(22)(iv) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1994-06-14 | (16) June 14, 1994, for products subject to paragraph (a)(25)(ii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2004-04-19 | (17) April 19, 2004, for products subject to paragraph (a)(3)(ii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2005-04-18 | April 18, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1995-08-15 | (18) August 15, 1995, for products subject to paragraph (a)(15)(ii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1987-10-02 | (19) October 2, 1987, for products subject to paragraph (a)(6)(iv)(A) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1996-01-29 | (20) January 29, 1996, for products subject to paragraph (a)(6)(iv)(B) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1994-04-21 | (21) April 21, 1994, for products subject to paragraph (a)(8)(iii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1993-04-21 | (22) April 21, 1993, for products subject to paragraph (a)(18)(ii) of this section that contain ferric subsulfate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1995-08-23 | (23) August 23, 1995, for products subject to paragraph (a)(6)(ii)(B) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1996-10-07 | (24) October 7, 1996, for products subject to paragraph (a)(2)(ii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1996-06-19 | (25) June 19, 1996, for products subject to paragraph (a)(6)(iv)(C) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 1999-02-22 | (26) February 22, 1999, for products subject to paragraphs (a)(23)(ii) and (a)(24)(ii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1998-10-22 | (27) [Reserved]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (28) October 22, 1998, for products subject to paragraphs (a)(27) and (a)(28)(i) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1999-01-29 | (29) January 29, 1999, for products subject to paragraph (a)(12)(iv)(B) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2002-11-05 | (30) November 5, 2002, for products subject to paragraph (a)(12)(iv)(C) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2002-12-31 | (31) December 31, 2002, for products subject to paragraph (a)(29)(i) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2004-06-04 | (32) June 4, 2004, for products subject to paragraphs (a)(18)(i)(B), (a)(18)(v)(B), and (a)(18)(vi)(B) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2005-06-06 | June 6, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 2001-10-29 | (33) October 29, 2001, for products subject to paragraph (a)(6)(iv)(D) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2004-12-09 | (34) December 9, 2004, for products subject to paragraph (a)(4)(ii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 2005-06-09 | June 9, 2005, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 2002-11-05 | (35) [Reserved]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (36) November 5, 2002, for products subject to paragraph (a)(28)(ii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 2003-09-25 | (37) September 25, 2003, for products subject to paragraph (a)(26)(xi) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2007-10-01 | (38) October 1, 2007, for products subject to paragraph (a)(12)(i)(B) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 2010-09-06 | (39) September 6, 2010, for products subject to paragraph (a)(18)(ii) of this section that contain calcium acetate monohydrate, except as provided in &#167;&#8201;347.20(b) of this chapter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 2012-12-17 | (40) December 17, 2012, for products subject to paragraph (a)(29)(ii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 2013-12-17 | December 17, 2013, for products with annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 2017-09-06 | (41) September 6, 2017, for products subject to paragraph (a)(27)(iii) or (iv) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1995-02-22 | (d) After February 22, 1995, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1998-04-20 | (d) After April 20, 1998, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1999-09-16 | (d) After September 16, 1999, any such OTC drug product containing colloidal silver or silver salts initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |


